London, UK and Carlsbad, CA, USA – 13 May 2021 – DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, has appointed Richard Hammond as Vice President of Technology.
Richard has worked for over 20 years in the field of medical device development, at the intersection of biology and engineering. He has extensive leadership and program management experience, primarily focused on developing products for regulated markets. He also has experience working for government sponsors on major programs.
He joins DNAe following six years with Cambridge Consultants where he held the positions of Technology Director and Head of Bioinnovation. The Bioinnovation team, which Richard established, built, and led, delivers technology development services at the overlap between biology, engineering, and computation.
Prior to this, Richard was Program Manager of R&D at Alere Inc. (now Abbott Rapid Diagnostics), where he led the team that developed the Abbott ID Now platform, the world’s first CLIA-Waived point-of-care molecular test for infectious disease.
Richard holds a master’s degree in Engineering from the University of Cambridge.
Commenting on Richard’s appointment, Samuel Reed, CEO of DNAe, said: “We are pleased to welcome Richard to further strengthen our fantastic team. His extensive experience, technical insight and in-depth knowledge in medical device development will be a great asset as we work to bring our LiDia-SEQ™ diagnostic platform into the clinic and to market.”
Richard Hammond commented: “It’s great to be joining DNAe at an exciting stage of the Company’s development. The team has done a wonderful job to date in developing DNAe’s proprietary semiconductor sequencing technology into an end-to-end solution for use ultimately as a diagnostic. I look forward to building on this success and us delivering LiDia-SEQ™ to clinicians and other users.”
About DNAe – www.dnae.com
DNAe is commercializing its pioneering semiconductor sequencing technology for healthcare applications where rapid point-of-need diagnostics are of critical need, including infectious disease and cancer testing and monitoring. It is developing LiDia-SEQ™, a user-friendly, direct-from-specimen platform that performs genomic analysis on a microchip, to provide actionable information to clinicians.
DNAe’s initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. This includes a range of tests, starting with a groundbreaking test for bloodstream infections (BSI) and antimicrobial resistance (AMR), which uses whole blood specimens to detect and identify infections that lead to sepsis. This will provide clinicians with actionable information to help select the appropriate antibiotics to treat the disease. A pipeline of follow-on tests is in development for viruses and cancer testing and monitoring.
The Biomedical Advanced Research and Development Authority (BARDA), a division of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), awarded DNAe a contract worth up to $51.9 million, if all options are awarded, to develop its diagnostic platform, initially for antimicrobial-resistant infections.
A private company, with facilities in London, UK and Carlsbad, CA, USA, DNAe’s major shareholder is Genting Berhad, a Malaysian-based global investor with a growing portfolio of investments in cutting-edge life sciences companies.
For more information please contact: DNAe@Instinctif.com